Original Article

Palliative Radiotherapy Efficacy on Overall Survival in Advance Lung Cancer Palliative Radiotherapy in Lung Cancer

Ahmed Salih Alshewered , Ali Ahmed, Ahmed Labib, Manwar Alnaqqash

Ahmed Salih Alshewered
Misan Oncology center. Email: ahmedsalihdr2008@yahoo.com

Ali Ahmed
Alamal Onco center

Ahmed Labib
Alamal Onco center

Manwar Alnaqqash
Baghdad Univer
Online First: July 25, 2019 | Cite this Article
Alshewered, A., Ahmed, A., Labib, A., Alnaqqash, M. 2019. Palliative Radiotherapy Efficacy on Overall Survival in Advance Lung Cancer Palliative Radiotherapy in Lung Cancer. The Cancer Press 5(1, 2, 3, 4). DOI:10.15562/tcp.79

Background: Throughout the world, lung cancer accounts for 13% of the total cases of cancer and 18% of the cancer related deaths based on 2008 estimates. Lung cancer is the first most common cancer and the most common cause of cancer-related death in both men and women.

Aims of study: To assess the overall survival of Iraqi lung cancer patients that treated with palliative radiotherapy.

Patients and Methods: The retrospective study was conducted to investigate survival after palliative radiotherapy for patients with lung cancer that treated in Baghdad center for Radiotherapy treatment from 1st of Jan 2016 to end of Dec 2017 for 40 patients whom suffered from dyspnea, pain, hemoptysis, and Superior Vena cava obstruction .The Radiation Dose was 20 Gy/5 fractions were prescribe (85 % of cases). For each patient, individual data and information on primary and advanced disease were collected from health file records.

Results: The Overall survival of lung cancer rate was 32.5%, with mean of 19.4 months  and median 14 months. The SCC 29 (72.5%) was the commonest histopathology of lung cancer in our study. The adenocarcinoma was recorded in 9 (22.5%) and other histopathological subtypes recorded in 2 (5%). Males were more than females obtained with lung cancer in this study as 33 (82.5%), 7(17.5%), respectively. M : F ratio was 4:1.

Conclusions: Palliative RT should be an integral part of multimodal, interdisciplinary management of patients with incurable lung cancer.


Alberg AJ, Ford JG, Samet JM (2007). Epidemiology of lung cancer: ACCP evidence based clinical practice guidelines (2nd edition). Chest 132:29S–55S.

Warde P, Payne D (1992). Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890–895.

Janssen S, Kaesmann L, Schild SE, et al. (2016). Impact of the Radiation Dose and Completion of Palliative Radiotherapy on Survival in Patients Treated for Locally Advanced Lung Cancer. Anticancer Res.;36(4):1825- 1828.

Macbeth FR, Bolger JJ, Hopwood P et al (1996). Randomised trial of palliative two-fraction versus more intensive thirteen fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status . Clin. Oncol. , 8 , 167 – 175.

Van Oorschot B, Assenbrunner B, Schuler M, et al. (2014). Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer. Strahlenther Onkol. 190(3):270-275.

Rusch VW, Asamura H, Watanabe H, et al (2009). The IASLC Lung Cancer Staging Project. A proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer . J. Th oracic Oncol. , 4 , 568 – 577.

Spiro SG, Rudd RM, Souhami RL, et al (2004). Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life . Thorax , 59 , 828 – 836.

Neuberger JS, Gesell TF (2002). Residential radon exposure and lung cancer: Risk in non smokers. Health Phys 83:1–18.

No Supplementary Material available for this article.
Article Views      : 404
PDF Downloads : 175